Pennsylvania SB946 amends the Controlled Substance, Drug, Device and Cosmetic Act to monitor and address tianeptine-related adverse health events.
Pennsylvania SB946 amends the Controlled Substance, Drug, Device and Cosmetic Act to enhance monitoring of tianeptine-related adverse health events. The Department of Health must collect data from various sources, including health care providers and law enforcement agencies, to track incidents. The department will issue public advisories when necessary and may coordinate with local health departments and federal agencies. The bill also allows the department to promulgate rules and regulations to enforce these provisions.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.